Table 1

Table details of study type, follow-up and treatment outcomes

StudyStudy type, setting and year of data collectionNumber of patients treated with the azithromycin 5-day regimen: number (%) who did not have a test of cureNumber of patients (episodes) treated with azithromycin 1 g: number (%) who did not have a test of cureNumber eligible for inclusion*Time to test of cureSpecimen typeTreated with 5-day regimenTreated with 1 g regimen
TotalFailure (%)Resistance post treatment (%)TotalFailure (%)Resistance post treatment (%)
Anagrius 201315 Retrospective case note study of patients with MG. Swedish STD clinic (1998–2005)19 male and 16 female: 9 (25.7)72 male and 62 female:
17 (12.7)
139Up to 52 weeksUrethral swabs male and cervical swabs female250 (0)0 (0)114†*7† (6.1)7† (6.1)
Falk 201517 Prospective longitudinal cohort study comprising an observational study and a randomised treatment trial. Swedish STD clinics (2010–2014)25 male and 37 female: 9 (14.5)10 male and
female: 2 (13.3)
56Up to 26 daysUrine male and cervical swabs female463 (6.5)3 (6.5)101 (10.0)1 (10.0)
Gesink 201622 Prospective, cross-sectional study of patients with MG. Toronto Sexual Health Clinic (2013)12 male and female: 3 (16.6)112–4 weeksUrine male and female110 (0)0 (0)0
Bissessor 201523 Prospective cohort study of patients with MG. Melbourne Sexual Health Centre  (2012–2013)160 (male and female)‡:
5 (3.1)
992 and 4 weeksUrine male and genital tract swabs (high vaginal or cervical) female09911 (11.1)11 (11.1)
Couldwell 201319 Retrospective case note study of mainly male patients with MG.§ Western Sydney Sexual Health Centre (2008–2011)53 (54), (male, and female)§ 15 (27.8)12Median 46 days (12–273 days)Urine or urethral swab0124 (33.3)3 (25)
Ito 201125 Retrospective case note study of men with MG-positive NGU. Urology clinic in Sendai, Japan  (2006–2008)58 male:¶242–4 weeksUrine0247 (29.2)4 (16.7)
Twin 201221 Retrospective audit of MG- positive patients who returned for a test of cure. Melbourne Sexual Health Centre (2007–2009)25 female and 86
males:**
66Median 30 days (14–127 days)Urine or urethral swab men and cervical swab female06614 (21.2)14 (21.2)
Walker 201326 Prospective cohort study of patients with MG. Australian primary care clinics (2007–2008)38 (41) female:
9 (21.%)
284 weeksVaginal swab0283 (10.7)3 (10.7)
Total435823 (3.7)
(95% CI
0.8 to 10.3)
3 (3.7)
(95% CI
0.8 to 10.3)
35347 (13.3)
(95% CI
9.9 to 17.3)
43 (12.2)
(95% CI
9.0 to 16.1)
  • *Number of eligible study participants who had no pre-existing macrolide resistance mutations prior to treatment (see Methods section).†Three additional patients who experienced treatment failure were excluded due to missing or inconclusive pretreatment samples.

  • ‡Of the 155 patients reattending 112 (72.3%) were male and 43 (28%) female.

  • §At least two female partners of men with NGU were treated for MG during the study period and included in the study.

  • ¶This was a subpopulation study of 308 men of whom 58 had MG detected, it is unclear how many of these reattended and tested negative.24

  • **The number of MG-positive patients treated with azithromycin 1 g who did not reattend for a test of cure during the study period is not detailed.

  • MG, Mycoplasma genitalium; NGU,  non-gonococcal urethritis.